Abstract
The impact of tumor infiltrating lymphocytes (TILs) on survival was confirmed in various cancer types. Our study aims to investigate the prognostic role of TILs on survival in patients with primary and metastatic tumors in breast cancer patients. We retrospectively identified 29 patients with human epidermal growth factor receptor - 2 (HER2+) and HER2 - early breast cancer diagnosed between 2012 and 2018 at Institute of Oncology Prof. Dr. Al. Trestioreanu Bucharest and who subsequently experienced regional or distant recurrence confirmed by tumor biopsy/resection.
Highlights
The impact of tumor infiltrating lymphocytes (TILs) on survival was confirmed in various cancer types
Previous studies have reported that immune activation at the baseline, as assessed by pathology or gene expression arrays, is associated with a higher likelihood of pathological complete response after neoadjuvant chemotherapy (NAC) [13,14], in human epidermal growth factor receptor-2 (HER2)-positive and HER 2 negative breast cancers [15,16]
Our study aims to investigate the prognostic role of TILs on survival in patients with primary and metastatic tumors in breast cancer patients
Summary
The impact of tumor infiltrating lymphocytes (TILs) on survival was confirmed in various cancer types. The presence of tumor-infiltrating lymphocytes (TILs) is associated with favorable with good prognostic in breast cancer [11,12]. Previous studies have reported that immune activation at the baseline, as assessed by pathology or gene expression arrays, is associated with a higher likelihood of pathological complete response after neoadjuvant chemotherapy (NAC) [13,14], in human epidermal growth factor receptor-2 (HER2)-positive and HER 2 negative breast cancers [15,16].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
